New Age Alpha Advisors LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 70,340 shares of the biotechnology company's stock, valued at approximately $8,553,000. New Age Alpha Advisors LLC owned approximately 0.07% of Sarepta Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SRPT. Commerce Bank raised its stake in shares of Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company's stock valued at $252,000 after acquiring an additional 274 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Sarepta Therapeutics by 1.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company's stock valued at $76,401,000 after purchasing an additional 6,992 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in Sarepta Therapeutics by 13.8% in the third quarter. Daiwa Securities Group Inc. now owns 3,929 shares of the biotechnology company's stock valued at $490,000 after buying an additional 475 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Sarepta Therapeutics by 1.3% during the third quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company's stock worth $2,267,000 after purchasing an additional 239 shares during the last quarter. Finally, Qsemble Capital Management LP acquired a new position in Sarepta Therapeutics in the third quarter valued at approximately $311,000. Hedge funds and other institutional investors own 86.68% of the company's stock.
Sarepta Therapeutics Price Performance
Shares of Sarepta Therapeutics stock traded up $0.07 during trading on Tuesday, reaching $63.89. The company's stock had a trading volume of 1,181,177 shares, compared to its average volume of 1,363,829. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $62.50 and a 12-month high of $173.25. The company has a market capitalization of $6.20 billion, a P/E ratio of 51.11 and a beta of 0.79. The business has a 50 day moving average price of $101.57 and a 200-day moving average price of $115.47.
Insider Buying and Selling at Sarepta Therapeutics
In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.70% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
SRPT has been the subject of several recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Finally, Scotiabank cut their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $164.05.
Read Our Latest Stock Report on SRPT
About Sarepta Therapeutics
(
Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
